Avacta is a pre-clinical stage biotechnology company developing biotherapeutics based on its proprietary Affimer protein technology that benefits from near-term revenues from research and diagnostic reagents. As a proven platform technology able to address multiple markets, the downside risk for Affimers is low, with significant potential as the Group builds a pipeline of valuable drug assets for development and licensing. Avacta aims to continue to grow revenue and convert on-going Affimer diagnostics and reagents evaluations into multiple license deals that will deliver long term royalties and a profitable Affimer reagents business unit.
As a public company we wanted to inform the market of our progress, through news flow. There is broker research of course, but it is not distributed to the non-institutional/retail market. We needed someone that could write informed research to the same institutional quality, and distribute it to a wider audience.
Alastair Smith, Chief Executive Officer